News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
736,324 Results
Type
Article (44675)
Company Profile (274)
Press Release (691365)
Multimedia
Podcasts (191)
Webinars (17)
Section
Business (208792)
Career Advice (2633)
Deals (36044)
Drug Delivery (144)
Drug Development (83820)
Employer Resources (181)
FDA (16745)
Job Trends (15282)
News (353941)
Policy (33437)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2681)
Accelerated approval (31)
Adcomms (32)
Allergies (142)
Alliances (50338)
ALS (177)
Alzheimer's disease (1705)
Antibody-drug conjugate (ADC) (331)
Approvals (16974)
Artificial intelligence (536)
Autoimmune disease (150)
Automation (37)
Bankruptcy (370)
Best Places to Work (11871)
BIOSECURE Act (22)
Biosimilars (194)
Biotechnology (179)
Bladder cancer (160)
Brain cancer (59)
Breast cancer (646)
Cancer (4869)
Cardiovascular disease (416)
Career advice (2223)
Career pathing (40)
CAR-T (290)
CDC (53)
Celiac Disease (2)
Cell therapy (775)
Cervical cancer (37)
Clinical research (71300)
Collaboration (1710)
Company closure (4)
Compensation (1148)
Complete response letters (61)
COVID-19 (2813)
CRISPR (94)
C-suite (873)
Cystic fibrosis (149)
Data (6211)
Decentralized trials (2)
Denatured (69)
Depression (142)
Diabetes (502)
Diagnostics (6785)
Digital health (44)
Diversity (13)
Diversity, equity & inclusion (47)
Drug discovery (252)
Drug pricing (209)
Drug shortages (32)
Duchenne muscular dystrophy (237)
Earnings (90415)
Editorial (61)
Employer branding (22)
Employer resources (160)
Events (118717)
Executive appointments (1021)
FDA (19881)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1488)
Gene editing (206)
Generative AI (45)
Gene therapy (637)
GLP-1 (1045)
Government (4849)
Grass and pollen (6)
Guidances (383)
Healthcare (19415)
HIV (58)
Huntington's disease (50)
IgA nephropathy (81)
Immunology and inflammation (269)
Immuno-oncology (58)
Indications (105)
Infectious disease (3088)
Inflammatory bowel disease (199)
Inflation Reduction Act (17)
Influenza (112)
Intellectual property (244)
Interviews (464)
IPO (16785)
IRA (54)
Job creations (3743)
Job search strategy (1829)
JPM (68)
Kidney cancer (15)
Labor market (85)
Layoffs (591)
Leadership (38)
Legal (8080)
Liver cancer (92)
Longevity (14)
Lung cancer (659)
Lymphoma (373)
Machine learning (42)
Management (63)
Manufacturing (807)
MASH (167)
Medical device (14088)
Medtech (14140)
Mergers & acquisitions (20323)
Metabolic disorders (1329)
Multiple sclerosis (161)
NASH (23)
Neurodegenerative disease (332)
Neuropsychiatric disorders (95)
Neuroscience (2971)
Neurotech (1)
NextGen: Class of 2026 (6817)
Non-profit (4720)
Now hiring (65)
Obesity (640)
Opinion (311)
Ovarian cancer (166)
Pain (204)
Pancreatic cancer (226)
Parkinson's disease (287)
Partnered (33)
Patents (493)
Patient recruitment (477)
Peanut (58)
People (61352)
Pharmaceutical (63)
Pharmacy benefit managers (31)
Phase 1 (22736)
Phase 2 (31265)
Phase 3 (23176)
Pipeline (5141)
Policy (317)
Postmarket research (2590)
Preclinical (9354)
Press Release (64)
Prostate cancer (241)
Psychedelics (53)
Radiopharmaceuticals (287)
Rare diseases (870)
Real estate (6066)
Recruiting (72)
Regulatory (24961)
Reports (51)
Research institute (2483)
Resumes & cover letters (445)
Rett syndrome (28)
RNA editing (20)
RSV (80)
Schizophrenia (152)
Series A (250)
Series B (191)
Service/supplier (11)
Sickle cell disease (102)
Special edition (25)
Spinal muscular atrophy (162)
Sponsored (41)
Startups (3725)
State (2)
Stomach cancer (20)
Supply chain (109)
Tariffs (89)
The Weekly (120)
Vaccines (1055)
Venture capital (94)
Weight loss (430)
Women's health (92)
Worklife (22)
Date
Today (58)
Last 7 days (606)
Last 30 days (2040)
Last 365 days (30354)
2026 (2932)
2025 (30750)
2024 (35931)
2023 (40826)
2022 (51838)
2021 (56460)
2020 (54985)
2019 (47827)
2018 (36227)
2017 (33065)
2016 (32470)
2015 (38379)
2014 (32020)
2013 (27103)
2012 (29296)
2011 (29955)
2010 (27867)
Location
Africa (838)
Alabama (86)
Alaska (7)
Arizona (308)
Arkansas (13)
Asia (40429)
Australia (6733)
California (11236)
Canada (3260)
China (1120)
Colorado (478)
Connecticut (474)
Delaware (335)
Europe (88689)
Florida (1672)
Georgia (357)
Hawaii (3)
Idaho (62)
Illinois (882)
India (62)
Indiana (518)
Iowa (22)
Japan (423)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1392)
Massachusetts (8075)
Michigan (320)
Minnesota (634)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (121)
New Hampshire (83)
New Jersey (2977)
New Mexico (29)
New York (2968)
North Carolina (1493)
North Dakota (8)
Northern California (5460)
Ohio (330)
Oklahoma (22)
Oregon (42)
Pennsylvania (2266)
Puerto Rico (22)
Rhode Island (48)
South America (1205)
South Carolina (65)
South Dakota (1)
Southern California (4377)
Tennessee (173)
Texas (1744)
United States (39977)
Utah (336)
Vermont (1)
Virginia (261)
Washington D.C. (82)
Washington State (916)
West Virginia (4)
Wisconsin (109)
Wyoming (2)
736,324 Results for "i peace inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
February 4, 2026
·
2 min read
·
Heather McKenzie
Earnings
AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas
On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.
February 4, 2026
·
2 min read
·
Dan Samorodnitsky
Biotech Bay
Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine
Heartseed Inc., a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure and I Peace Inc., a leading GMP cell CDMO in Palo Alto, California, have collaborated to generate cardiomyocytes using multiple donor-derived iPS cell lines produced by I Peace and Heartseed’s proprietary cardiomyocytes differentiation and purification methods.
November 1, 2023
·
3 min read
Press Releases
/C O R R E C T I O N from source -- argenx Canada Inc./
November 6, 2025
·
7 min read
Press Releases
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
February 8, 2026
·
7 min read
Press Releases
/C O R R E C T I O N -- Sanofi-Aventis Canada Inc./
October 21, 2025
·
8 min read
I Peace partners with the California Institute for Regenerative Medicine [CIRM]
PRNewswire -- I Peace, Inc. announced that the company has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to pave way for the provision of Good Manufacturing Practice (GMP) iPSCs for various research programs funded by CIRM. I Peace has been providing
November 1, 2022
·
3 min read
I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with “Special Recognition in Cell Therapy”
I Peace, Inc. is a Palo Alto-based biotech company focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) and has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette.
December 22, 2022
·
2 min read
Immunology and inflammation
Novartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the third quarter, the pipeline-in-a-product strategy has never been more attractive.
November 12, 2025
·
6 min read
·
Heather McKenzie
Press Releases
Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies
December 3, 2025
·
7 min read
1 of 73,633
Next